Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback